Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$9.028M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
0.74%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$8.922M
Q3 2024
Cash
Q3 2024
P/E
-1.694
Nov 29, 2024 EST
Free Cash Flow
-$1.308M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019
Revenue $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019
Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019
Selling, General & Admin $8.253M $26.61M $1.739M $2.111M $342.3K
YoY Change -68.98% 1430.39% -17.64% 516.73%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $638.5K $704.7K $751.8K $837.9K $528.2K
YoY Change -9.39% -6.26% -10.27% 58.64%
% of Gross Profit
Operating Expenses $8.891M $27.31M $2.491M $2.949M $870.5K
YoY Change -67.45% 996.72% -15.55% 238.78%
Operating Profit -$8.891M -$27.31M -$2.490M
YoY Change -67.45% 996.72%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019
Interest Expense -$1.630K -$213.0K
YoY Change -99.23%
% of Operating Profit
Other Income/Expense, Net -$4.016M $213.0K
YoY Change -1985.44%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019
Pretax Income -$12.91M -$27.53M -$2.491M -$3.053M -$870.5K
YoY Change -53.1% 1005.28% -18.42% 250.7%
Income Tax $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$13.13M -$27.66M -$2.491M -$3.053M -$870.5K
YoY Change -52.54% 1010.7% -18.42% 250.7%
Net Earnings / Revenue
Basic Earnings Per Share -$0.07 -$0.17 -$0.02
Diluted Earnings Per Share -$0.07 -$0.17 -$15.73K -$19.28K -$5.497K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019
Cash & Short-Term Investments $10.06K $414.6K $1.283M $102.3K $0.00
YoY Change -97.57% -67.68% 1154.22%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $258.2K $77.85K $168.2K $19.07K $58.35K
YoY Change 231.7% -53.72% 782.17% -67.32%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $268.3K $492.4K $1.451M $121.3K $58.35K
YoY Change -45.52% -66.06% 1095.64% 107.95%
Property, Plant & Equipment $16.41M $17.15M $7.329M $7.778M $8.601M
YoY Change -4.31% 133.96% -5.77% -9.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $726.3K $3.991M
YoY Change -81.8%
Other Assets $0.00 $1.158M
YoY Change -100.0%
Total Long-Term Assets $17.13M $22.30M $7.330M $7.779M $8.601M
YoY Change -23.15% 204.18% -5.77% -9.56%
Total Assets $17.40M $22.79M $8.781M $7.900M $8.659M
YoY Change
Accounts Payable $4.175M $5.034M $149.9K $180.3K $82.75K
YoY Change -17.06% 3257.23% -16.86% 117.93%
Accrued Expenses $411.1K $447.3K $18.03K $116.3K $89.62K
YoY Change -8.1% 2381.03% -84.5% 29.8%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.236M $7.523M $168.0K $296.7K $172.4K
YoY Change -17.11% 4379.25% -43.38% 72.12%
Long-Term Debt $201.8K $3.686M $0.00 $0.00 $0.00
YoY Change -94.53%
Other Long-Term Liabilities $0.00 $392.2K $382.6K $0.00
YoY Change -100.0% 2.51%
Total Long-Term Liabilities $201.8K $3.686M $392.2K $382.6K $0.00
YoY Change -94.53% 839.88% 2.51%
Total Liabilities $6.438M $11.21M $560.2K $679.3K $172.4K
YoY Change -42.57% 1901.12% -17.54% 294.1%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019
Basic Shares Outstanding 178.6M shares 162.1M shares 156.8M shares
Diluted Shares Outstanding 178.6M shares 162.1M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $15.293 Million

About Bright Green Corp

Bright Green Corp. engages in the cultivation, manufacture, and sale of medical cannabis. The company is headquartered in Fort Lauderdale, Florida and currently employs 5 full-time employees. The company went IPO on 2022-05-17. The firm specializes in the research, production, distribution, and advancement of plant-based drugs and APIs, including psilocybin, psilocyn, peyote, and opium poppy. The company plans to focus on the development of cannabis strains and sales of cannabis and hemp products with high contents of cannabinol (CBN) and cannabigerol (CBG). The company also plans to cultivate cannabis and focus on the production of dried flowers, and oils and marijuana extracts. In addition to cannabis, it also has a separate area for controlled substance cactus cultivation, and a separate controlled area for mushroom propagation. The company is in the process of completing construction of the 22-acre existing greenhouse to comply with the requirements for Schedule I and Schedule II plant-based drugs. The company also plans to construct two new 57-acre greenhouses, one each on the Candelaria property and Azuz property.

Industry: Medicinal Chemicals & Botanical Products Peers: HARROW, INC. Citius Pharmaceuticals, Inc. JOHNSON & JOHNSON ZEVRA THERAPEUTICS, INC. OMEROS CORP RVL Pharmaceuticals plc Rain Oncology Inc. Satsuma Pharmaceuticals, Inc. Terns Pharmaceuticals, Inc. Xeris Biopharma Holdings, Inc.